Study of efficacy and safety of pasireotide LAR in patients with inadequately controlled acromegaly.

Registry ID

EUCTR2014-002630-31

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Novartis Pharma Services AG

Start date

2015-03-25

Completion date

2018-09-27

Last update

2026-08-16

Conditions

• Acromegaly

Summary

Primary objective: - To evaluate the efficacy of pasireotide LAR in patients with acromegaly who are inadequately controlled with maximal approved doses of currently available somatostatin analogues Supporting Analysis for Primary objective: - To assess the proportion of patients achieving GH <1µg/L and IGF-1 <ULN by GH level.

Locations

• , , Bulgarian Drug Agency
• , , Belgium
• , , France
• , , Hungary
• , , Portugal
• , , Italy

Related clinical trials

• An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
• A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
• Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA
• Study of MAR002 in Healthy Men
• Effects of Pasireotide Lar Therapy on Bone Metabolism
• Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional Study

View on source registry